ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

2022 ESMO World Congress on Gastrointestinal Cancer

 

29 June – 2 July 2022 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-O Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study Aiwu Ruth He Received Received
  1-PD The impact of COVID-19 on diagnosis, stage and treatment of esophageal and gastric cancer Jeanne Bakx Received Received
  2-PD EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinoma Susanna Slater Received Received
  2-O Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202 Arndt Vogel Received Received
  2-SO Comparison of resected vs non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study David Turner Received Received
  2-P Modified GTX second-line therapy in pancreatic adenocarcinoma: An updated analysis Maria Mezher Received Received
  3-P Gastric cancer prognosis and cell ratio factors Oleg Kshivets Received Received
  3-PD Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial Hirokazu Shoji Received Received
  3-SO Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma margherita rimini Received Received
  4-P Efficacy and safety of sintilimab combined nab-paclitaxel and gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC): A retrospective analysis Jianzheng Wang Received Received
  4-O Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophago-gastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas) Per Pfeiffer Received Received
  4-PD Genetic aberration from normal tissues adjacent to biliary tract cancers Dong Uk Kim Received Received
  5-P Phase II study (daNIS-1) of the anti-TGF- monoclonal antibody (mAb) NIS793 /- spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) Faye Hudson Received Received
  5-O Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study Arndt Vogel Received Received
  5-PD IDH1 in intrahepatic cholangiocarcinoma: A comparative genomic analysis and clinical impact margherita rimini Received Received
  6-P Prognostic value of the lymphocyte/monocyte ratio in advanced pancreatic cancer Wala BEN KRIDIS Received Received
  6-PD DNA methylome as a potential biomarker in biliary brushes and bile fluid samples to differentiate between benign and malignant biliary stenosis Sarah Cappuyns Received Received
  7-SO Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial Cheryl Lucania Received Received
  7-P Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria - BERING CRC Frank Reichenbach Received Received
  7-PD Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study Donna Stefanoni Received Received
  7-O Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately ed patients: Findings from long-term follow-up of CRICKET and CAVE trials Erika Martinelli Received Received
  8-PD Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study Takuji Okusaka Received Received
  8-P Long-term survival in patients with pancreatic cancer (PAC) treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI5-FU/LV) Gerald Prager Received Received
  8-SO Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR) Hisato Kawakami Received Received
  9-SO Pathological primary tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trials. Avani Athauda Received Received
  9-PD Three arm phase II/III randomized controlled trial in patients with unresectable/metastatic gall bladder cancer with poor performance status: Erlotinib or capecitabine v/s best supportive care Babita Kataria Received Received
  9-P Gallbladder cancer in the United States: Identifying factors associated with failure to treat McKenzie White Received Received
  10-SO The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients: Results from the UK MRC OE02 trial Maximilian Kloft Received Received
  10-PD Comprehensive circulating tumor (ct) DNA NGS for molecular profiling in advanced cholangiocarcinoma Laura Visa Received Received
  11-PD In depth analysis of label-free infrared (IR) imaging-based microsatellite instability (MSI) classification in early colon cancer (CC) on samples from the AIO ColoPredictPlus 2.0 (CPP) registry trial Daniel Zaldumbide Received Received
  12-P A phase 3 study of nivolumab (NIVO), NIVO ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW Thierry André Received Received
  12-SO Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040 Luis Pichardo Received Received
  12-PD Characterization of best responder patients to oxaliplatin rechallenge in patients with refractory metastatic colorectal cancer (mCRC) Francesc Salvà Received Received
  13-PD Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials Yoshinori Kagawa Received Received
  14-SO Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study Andrea Casadei-Gardini Received Received
  14-PD Resectability, conversion, and resection rates with survival according to RAS and BRAF mutations in a prospective metastatic colorectal cancer study (liver-limited subgroup in the RAXO study) Pia Osterlund Received Received
  14-P Safety and short-term efficacy of preoperative FOLFOX therapy for patients with resectable esophageal squamous cell carcinoma who are not candidates for cisplatin Toru Kadono Received Received
  15-SO Impact of sequencing of different treatment modalities on survival outcomes among patients with non-metastatic hepatocellular carcinoma Firas Baidoun Received Received
  15-P Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease Hisato Kawakami Received Received
  16-P PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement Lee Miller Received Received
  17-SO A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX /- bevacizumab versus FOLFOX /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer Feng Wang Received Received
  17-P Real-life use and long-term effectiveness results from CIREL - the multi-centre, observational study on irinotecan-eluting transarterial chemoembolization in CRLM Bleranda Zeka Received Received
  18-P Prognostic association between over expression of vascular endothelial growth factor receptor and micro vascular invasion in patients with hepatocellular carcinoma Nandin-Erdene Enkhbaatar Received Received
  18-SO Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies Lucjan Wyrwicz Received Received
  19-P Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC) Philippe Merle Received Received
  20-P Predictors of distant relapse in rectal cancer patients submitted to preoperative chemoradiotherapy Fátima Aires Received Received
  20-SO Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial Cezanne Golley Received Received
  21-SO Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials Alessandra Raimondi Received Received
  21-P Molecular subtypes (profile) of colorectal cancer and their correlation with clinical and pathological profile in a tertiary care centre in India Srujana Joga Received Received
  22-SO Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer Morteza RAEISI Received Received
  22-P Phase III study (daNIS-2) of the antiTGF- monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma Maya Schamroth Rossade Received Received
  23-P Phase II study (daNIS-3) of the antiTGF- monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer Maya Schamroth Received Received
  23-SO Real-world evaluation of clinical utility of ColonAiQ, a blood-based assay for colorectal cancer (CRC) early detection Fan li Received Received
  24-P Gender differences in overall survival in patients with metastatic pancreatic cancer Hossein Taghizadeh Received Received
  24-SO Young age as bad prognosis of colorectal cancer: An earlier screening needed? German Calderillo-Ruiz Received Received
  25-P Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation Zhenggang Ren Received Received
  25-SO Total neoadjuvant therapy (TNT) in early-onset (EO) vs average-onset (AO) locally advanced rectal cancer (LARC): Patient characteristics and tolerance Madison Conces Received Received
  26-P HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2) advanced/metastatic gastroesophageal adenocarcinoma (GEA) Mayank Singh Received Received
  26-SO Identification and quantification of the microbiome in colorectal cancer metastases Philippe Stevens Received Received
  27-P Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer Thierry André Received Received
  28-P RealWorld Observational Study of MVASI in Metastatic Colorectal Cancer Patients in Canada: Baseline Patient Characteristics Mistre Alemayehu Received Received
  28-SO Gut microbiome characterization and correlation with colonoscopy findings in oncological and non-oncological patients from a Chilean cancer center Franz Villarroel-Espindola Received Received
  29-SO Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: Prevalence and correlation between DPYD-genotype mutations and P-uracil concentrations Niels Paulsen Received Received
  29-P Overall survival and treatment patterns in patients with metastatic colorectal cancer: a retrospective chart review Courtney Laney Received Received
  30-P First-line (1L) treatment patterns in advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma (GC/GEJC/EAC): Data from the Spanish AGAMENON-SEOM registry Courtney Laney Received Received
  30-SO Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma Kazuaki Harada Received Received
  31-SO Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset Luke Springall Received Received
  32-P Different regimens of the 1st line chemotherapy in patients (pts) with metastatic anal cancer: Results of the multicenter observational study Mikhail Fedyanin Received Received
  33-P Prognostic impact of single organ pulmonary metastasis in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy Hiroki Osumi Received Received
  34-P Does the chemotherapeutic efficacy of trifluridine/tipiracil plus bevacizumab change depend on pre-treatment vascular endothelial growth factor inhibitors? Hiroki Osumi Received Received
  35-P An observational study of health-related quality of life(HRQoL)with electronic patient-reported outcome(ePRO)monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment:NIVO-G QoL study Hisato Kawakami Received Received
  36-P Real-world outcomes in BRAFV600E metastatic colorectal cancer - the Glasgow experience Hao Wen Gerald Gan Received Received
  36-SO An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study Carlotta Antoniotti Received Received
  37-SO Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib cetuximab binimetinib: Subanalysis of BEACON CRC Christina Puzzolo Received Received
  38-P Proper size and timing of endoscopic dilation in anastomotic stricture after near-total esophagectomy Dae Gon Ryu Received Received
  39-P Utility of circulating tumor DNA (ctDNA) to assess tumor response in patients with locally advanced rectal cancer undergoing neoadjuvant therapy Sakti Chakrabarti Received Received
  39-SO Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100 Hans Prenen Received Received
  40-P Clinico-pathological characteristics and outcomes of patients with early-onset colorectal cancer David Viñal Received Received
  40-SO Measurement of circulating tumor DNA (ctDNA) in appendiceal adenocarcinoma (AA): Prevalence, predictors, and correlation with clinical outcome Mohammad A. Zeineddine Received Received
  41-P What to expect from best supportive care as initial approach for newly-diagnosed colorectal cancer: A single institution experience David Viñal Received Received
  44-P Impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer Cezanne Golley Received Received
  45-P Microsatellite instability and HER2 status in radically resectable locally advanced esophago-gastric adenocarcinoma Lorenzo Gervaso Received Received
  49-P GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab safety and preliminary response results Maike Collienne Received Received
  50-P RETRO-TAS, a retrospective observational study of trifluridine/ tipiracil in chemorefractory metastatic colorectal cancer ANNA KOUMARIANOU Received Received
  51-P Non-invasive HER2 status diagnosis in gastric cancer using surrogate DNA methylation markers Xin Liu Received Received
  52-P FOLFIRI or FOLFOX in second line of advanced biliary tract cancer: A retrospective analysis Matheus Balarine Received Received
  53-P A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma Laura-Carolin Hasenkamp Received Received
  55-P Efficacy and safety data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Real-world data from the non-interventional TACTIC study Frank Hartmann Received Received
  56-P Estimating endpoint correlation between surrogate measures and overall survival using reconstructed survival data: Case studies from adjuvant and metastatic gastric cancer trials Murat Kurt Received Received
  57-P An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18) Yu Sunakawa Received Received
  58-P Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol Florian Huemer Received Received
  59-P Real-world data of trastuzumab in metastatic gastric cancer Ana Vasques Received Received
  60-P Unrecognized development of chemoresistance and/or distant metastases during induction chemotherapy for pancreatic adenocarcinoma Hussein Gharib Received Received
  61-P Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy Hiroshi Matsuoka Received Received
  62-P Characterization and management of cholangiocarcinoma in a tertiary hospital with a high volume of patients Inmaculada Gallego Jiménez Received Received
  63-P Efficacy, safety and prognostic subgroups for outcome with regorafenib in patients with refractory metastatic colorectal cancer in the real-world setting: The CORE study Nieves Purificacion Martinez Lago Received Received
  64-P Incidence of brain metastases in a potentially high-risk group of patient with metastatic colorectal cancer: Results from a pilot study Louise Callesen Received Received
  65-P Stereotactic radiosurgery for palliative management of hepatocellular carcinoma associated with portal vein thrombosis Khaled AbdelKarim Received Received
  66-P PET/CT radiomic features to predict clinical outcomes in locally advanced pancreatic cancer Michele Fiore Received Received
  67-P Comparison of the malignant predictors in intrahepatic and extrahepatic intraductal papillary neoplasm of bile duct Dong Uk Kim Received Received
  69-P Anal squamous cell carcinoma (ASCC) outcomes in clinical practice: From localized to metastatic setting Jorge Esteban Villarrubia Received Received
  70-P Outcomes following FGFR inhibitor therapy in patients with cholangiocarcinoma: Multi-center single institution cohort experience Jennifer Gile Received Received
  72-P Real-world treatments and outcomes for biliary tract cancer patients using administrative databases in Ontario, Canada Iqra Syed Received Received
  73-P Survival outcomes of surgical resection in perihilar cholangiocarcinoma in endemic area of O. Viverrini, Thailand Poowanai Sarkhampee Received Received
  74-P SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress) Natalie Pizzimenti Received Received
  76-P Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD) Naotoshi Sugimoto Received Received
  77-P A phase II study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma Milind Javle Received Received
  78-P A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis Hiroshi Tamagawa Received Received
  80-P A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study Toshiki Masuishi Received Received
  81-P Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1positive metastatic colorectal cancer (mCRC) Jose Casasnovas Received Received
  82-P Evaluation of prognostic tools in locally-advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy Pablo Gómez Mugarza Received Received
  83-P The impact of the multidisciplinary team (MDT) in the management of colorectal cancer (CRC) Francesco Schietroma Received Received
  84-P Can a patient navigator increase quality of life in colorectal cancer patients? The WeGuide trial Patrícia Semedo Received Received
  85-P Pre-surgical staging and surveillance after curative treatment for pancreatic ductal adenocarcinoma (PDAC): Survey of practice in the United Kingdom (UK) Angela Lamarca Received Received
  86-P First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis 2-year follow-up Onaisa Rizki Received Received
  87-P Clinical score to predict recurrence in patients with stage II and III colon cancer David Viñal Received Received
  88-P Clinical role of tumour markers in advanced biliary cancers (ABC) treated with second-line active-symptom-control(ASC) alone or ASC with oxaliplatin/5-FU chemotherapy(ASCmFOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial Angela Lamarca Received Received
  89-P Real-world utility of full staging with 18-fluorodeoxyglucose positron emission tomography (18FDG-PET) in addition to standard imaging in patients with non-metastatic non-resectable pancreatic ductal adenocarcinoma (PDAC) Angela Lamarca Received Received
  90-P First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis Abdurrahman Isikdogan Received Received
  91-P Quality of life (QoL)-based end-points for patients with advanced pancreatic ductal adenocarcinoma (aPDAC): Results from the PanDA prospective observational study Angela Lamarca Received Received
  92-P Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study Mehmet Artac Received Received
  93-P The role of combined treatment of metastatic colorectal cancer in patients with liver metastases Danila Gridnev Received Received
  94-P Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial Daphne Day Received Received
  95-P Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study Kentaro Yamazaki Received Received
  96-P Quality of life in late stage cancer patients on immune checkpoint inhibitor therapy James Boyle Received Received
  97-P DNA Damage Repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study Maria Bensi Received Received
  98-P Diabetes promotes the progression of pancreatic ductal adenocarcinoma via the interaction between transforming acinar cells and cancer cells through AKT/CEBP/LCN2 pathway Tran Tran Received Received
  99-P A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G Toshiki Masuishi Received Received
  101-P Conditional relative survival in non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study Marieke Pape Received Received
  102-P Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: A retrospective analysis using US claims data Cezanne Golley Received Received
  103-P The importance of maintenance chemotherapy in the first and second line of treatment of metastatic colorectal cancer Danila Gridnev Received Received
  104-P Overexpression of mir-224-3p in extrahepatic cholangiocarcinoma associated with increased dose of I131 radiotherapy: An in vitro study Maria Clara Jessica Calastri Received Received
  105-P miR-145-3p subexpression, life habits and comorbidities in cholangiocarcinoma carcinogenesis pathway Pedro Henrique Fogaa Jordão Received Received
  106-P Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database Ofer Margalit Received Received
  109-P Care delivery impact of the COVID-19 pandemic on anal cancer care Erick Saldanha Received Received
  110-P Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer Angela Zhang Received Received
  112-P Oleic acid promotes the malignant transformation of Kras-mutant colonic organoids via the expansion of tumorigenic stem cells and abnormal Paneth cells through upregulation of NFATc family Vang Pham Received Received
  113-P A multicenter observational study of liposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Retrospective part Takashi Imajima Received Received
  114-P A seven-marker DNA methylation assay for non-invasive early detection of gastric cancer Weimei Ruan Received Received
  115-P Bevacizumab in metastatic colorectal carcinoma: A retrospective review of real-world efficacy Malcolm Buhagiar Received Received
  116-P Discriminating factors for gastric neoplasm among regenerative atypia found in screening upper gastrointestinal endoscopy Joo Hyun Lim Received Received
  117-P Circulating tumor DNA in metastatic colorectal cancer: Real-time monitoring of disease evolution and treatment response Giorgia Marisi Received Received
  118-P Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study Cristina Santos Vivas Received Received
  119-P Muscle quantity and quality in metastatic colorectal cancer patients during third-line therapy with regorafenib or TAS102 Chiara Maddalena Received Received
  120-P Front-line treatment of locally advanced pancreatic adenocarcinoma with tumour treating fields concomitant with gemcitabine and nab-paclitaxel: The phase 3 PANOVA-3 study Sinead Stewart Received Received
  121-P Effects of tumor treating fields (TTFields) on gastric cancer cells and their potential concomitant application with FOLFOX Sinead Stewart Received Received
  122-P Vitamin D-based score in gastric cancer Cousillas Antía Received Received
  123-P A Phase Ia/Ib, open-label, dose-escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy in patients with advanced gastrointestinal cancers Daniel Broadley Received Received
  124-P Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments: Balancing overall survival and quality of life Andrew Fox Received Received
  125-P Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC) Naftali Bechar Received Received
  126-P Clustering analysis identified three IDH1-mutated intrahepatic cholangiocarcinomas clusters with prognostic significance margherita rimini Received Received
  127-P Multi-institutional analysis of real-world activity and safety of trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer Gianluca Arrichiello Received Received
  128-P Pathologic complete response to neoadjuvant chemoradiation as a predictor of survival in Latin American patients with rectal cancer German Calderillo-Ruiz Received Received
  129-P Evaluation of HER2 status in equivocal gastric cancer tissue samples using surrogate DNA methylation markers Xin Liu Received Received
  130-P Latin American population with adenocarcinoma of the esophagogastric junction: A 9 year follow up German Calderillo-Ruiz Received Received
  131-P Low dose aspirin in combination with trans arterial chemo embolization in treatment of unresectable hepatocellular carcinoma Alshimaa Alhanafy Received Received
  132-P Plasma cfDNA methylation profiling and mRNA sequencing to monitor therapy response in esophageal adenocarcinoma patients Kathleen Schoofs Received Received
  133-P Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa or bintrafusp alfa plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301) Colleen Stanton Received Received
  134-P EV-202: an open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts Kei Muro Received Received
  135-P Capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis Bradley Ashley Ong Received Received
  136-P Prognostic implication of portal venous circulating tumor cells in resectable pancreatic cancer Seung Bae Yoon Received Received
  137-P Efficacy and safety of atezolizumab plus bevacizumab in unresectable or advanced hepatocellular carcinoma: Real life data from 5 Swiss centers Blanca Norero Received Received
  138-P Real-world delivery, toxicity and outcomes of perioperative FLOT chemotherapy in resectable gastric/ gastroesophageal adenocarcinoma: A population-based study Eric Di Gravio Received Received
  140-P Simple endoscopic scoring of patients with rectal cancer after concurrent chemoradiation therapy Seok Choi Received Received
  141-P Lenvatinib activates potential anti-tumor immunity by increasing infiltration of immune cells and interferon response in tumor microenvironment of advanced hepatocellular carcinoma Masami Yamauchi Received Received
  142-P Inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine: A single-center study George Papaxoinis Received Received
  143-P Using artificial intelligence CT-based methods to evaluate body composition for predicting survival outcomes in patients with colorectal cancer receiving PD-1 treatment Xici Liu Received Received
  144-P Quality of life assessment in biliary tract cancer: A systematic review of phase 2 and 3 clinical trials published between 2010 and 2021 Nastassja Tober Received Received
  145-P Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study Stefani Ioannou Received Received
  146-P The first comprehensive genomic characterization of rectal squamous cell carcinoma Christoforos Astaras Received Received
  148-P The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study Enrico Gurreri Received Received
  149-P Impact of COVID-19 pandemic and total neoadjuvant therapy (TNT) implementation in pathological complete response (pCR) rates in patients (pts) with locally advanced rectal cancer (LARC) Diego Gomez Puerto Received Received
  150-P Targeting loss of heterozygosity in colorectal cancer Natallia Rameika Received Received
  151-P PRO-based symptom management for patients with gastric and esophageal cancer who have undergone previous surgery Yifu He Received Received
  152-P Real-world data in patients with localized esophageal and gastroesophageal junction cancer undergoing surgery in France: Results from the FREGAT database Courtney Laney Received Received
  153-P Prospective collection of patient reported outcomes in patients with locally advanced rectal cancer receiving modern radiotherapy Christina Truelsen Received Received
  155-P Adjuvant therapy (AT) in patients (pts) with radically resected ampullary adenocarcinoma (AA): A monocentric retrospective analysis Diletta Barone Received Received
  156-P MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2 gastric or gastroesophageal junction adenocarcinoma: Trial in progress Joseph Giaconia Received Received
  157-P Impact of an educational activity on the competence of oncologists and gastroenterologists regarding the application of molecular-guided therapies for the treatment of advanced cholangiocarcinoma Ben Johnson Received Received
  158-P Comprehensive recurrence risk assessment after colectomy, for stage II and III colorectal cancer patients, using genetic profiling, microbiome, and circulating tumor markers Ippokratis Messaritakis Received Received
  159-P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study Brian Marcus Received Received
  160-P Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow German Calderillo-Ruiz Received Received
  161-P Trial in progress: Neoadjuvant combination therapy of lenvatinib plus transcatheter arterial chemoembolization (TACE) for transplant-eligible patients with large hepatocellular carcinoma Maen Abdelrahim Received Received
  162-P Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond Milan criteria Maen Abdelrahim Received Received
  163-P Tyrosine kinase inhibitors (TKIs) plus transarterial chemoembolization (TACE) compared to TACE alone as downstaging therapy in transplant recipients with hepatocellular carcinoma Abdullah Esmail Received Received
  164-P Postoperative skeletal muscle loss negatively impacts survival after pancreaticoduodenectomy in periampullary cancers Moon Hyung Choi Received Received
  165-P The feasibility of tumor recurrence detection in liver post-transplantation for patients with hepatocellular carcinoma via personalized, tumor-informed ctDNA testing Maen Abdelrahim Received Received
  166-P Local recurrence after endoscopic submucosal dissection of early gastric cancer Cheol Woong Choi Received Received
  167-P Identification of peptides inhibitor clade A member 1 as a novel serum biomarker for gastric cancer and promotes liver metastasis Weiyao Li Received Received
  168-P Combination of gemcitabine plus cisplatin compared to non-gemcitabine and cisplatin regimens as neo-adjuvant treatment in liver transplant recipients with cholangiocarcinoma Maen Abdelrahim Received Received
  169-P Feasibility of gemcitabine plus cisplatin as neo-adjuvant in cholangiocarcinoma patients prior to liver transplantation Abdullah Esmail Received Received
  170-P Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study) Feng Wang Received Received
  171-P Prognostic value of conversion from RAS-mutated to RAS wild-type during treatment of metastatic colorectal cancer using liquid biopsies - real-world data of two Portuguese institutions Joana Albuquerque Received Received
  172-P A multi-center, open-label, randomized controlled trial of nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer (PC) Min Jin Received Received
  173-P Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis Marta Peri Received Received
  174-P OPTIMISE: Optimization of treatment ion and follow-up in oligometastatic colorectal cancer a ctDNA-guided phase II randomized approach with a run-in feasibility part Karen-Lise Spindler Received Received
  175-P Local inflammatory biomarkers and their association with systemic inflammation as well as overall survival in primary metastatic gastroesophageal cancer patients Hannah Christina Puhr Received Received
  177-P Sex differences in chemotherapy-induced toxicities in gastric cancer patients Mafalda Teixeira da Costa Received Received
  178-P Diffusion-weighted magnetic resonance imaging as an early predictive marker of chemoradiotherapy response in squamous cell carcinoma of the anus: An individual patient data meta-analysis Bettina Hanekamp Received Received
  179-P Stereotactic body radiation therapy (SBRT) for lung metastases from colorectal cancer: A single-institution experience Susana Costa Received Received
  180-P Gastric cancer in Albania: Epidemiological, clinical and pathological characteristics Fatjona Kraja Received Received
  181-P Outcomes of neoadjuvant and/or adjuvant treatment vs surgical resection alone for patients with cholangiocarcinoma: An inverse probability of treatment weighting with predictive nomogram Hind Hassan Received Received
  183-P Hepatocellular carcinoma: 9 years of experience in the medical oncology department at Mohammed VI university hospital in Marrakech, Morocco GHIZLANE ELMOHADAB Received Received
  186-P A multicenter exploratory analysis of the possible predictive factors for trifluridine/tipiracil in refractory metastatic colorectal cancer Juraj Prejac Received Received
  187-P Epidermal growth factor receptor inhibitors (EGFRi) in patients with left-side, RAS wildtype metastatic colorectal cancer: Clinician use and outcomes for patients Jane McKenzie Received Received
  188-P Transgelin/PARP1 regulates colorectal cancer metastasis through Rho GTPase pathway Zhen Ye Received Received
  189-P Variant detection and personalized treatment in colorectal cancer Panagiotis Apsotolou Received Received
  190-P The Geriatric 8 score is associated with risk of hospitalisation and 6-month survival in patients with incurable pancreatic cancer receiving gemcitabine and capecitabine Conor ONeill Received Received
  191-P Ampullary neoplasms how to treat in real-world practice? A retrospective study Mariana Sardinha Received Received
  192-P Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumors sensitive to imatinib: A retrospective analysis of 2 Russian cancer centers Daria Filonenko Received Received
  193-P DPYD evaluation and dose adjustment in patients with gastrointestinal cancer before initiation of fluoropyrimidine-based chemotherapy: One-centre experience Marta Vilaa Received Received
  195-P A cohort of patients (pt) with HER2-positive (HER2) advanced gastroesophageal cancer (aGEC) treated at our institution after a decade of tailored targeted therapy Anna Pous Badia Received Received
  196-P Circulating tumor DNA as a prognostic biomarker in pancreatic cancer patients treated with FOLFIRINOX: A prospective cohort study Jung Won Chun Received Received
  197-P Impact of local treatments on survival of patients with liver metastases from colorectal cancer (CRC) in real-life setting Mirjana Pavlovic Mavic Received Received
  198-P A scoring model to predict the clinical outcome of self-expandable metal stents in patients with colorectal obstruction due to extracolonic malignancy Yuna Kim Received Received
  199-P Oxaliplatin desensitization in coloretal cancer: A way to prolong effective treatments Helena Guedes Received Received
  200-P Mutational testing on liquid biopsies for treatment decisions in metastatic colorectal cancer comparison of ddPCR and MassARRAY methods Louise Callesen Received Received
  201-P Using SBRT in treating oligorecurrences of carcinoma of stomach Rahul Krishnatry Received Received
  202-P Increased expression of Noggin in pancreatic cancer is associated with patients poor survival Ming Liu Received Received
  203-P Epidemiological and pathological profile of colon cancer in young people: A report on 70 patients GHIZLANE ELMOHADAB Received Received
  204-P Outcomes of geriatric population with resectable colorectal liver metastases cancer: Data from real life Mariana Jorge Costa Received Received
  205-P Concordance between RAS and BRAF mutational status determination in ctDNA and tissue in patients with mCRC Eduardo Terán Brage Received Received
  206-P Association between primary tumor site of colorectal cancer and RAS/BRAF mutational status with venous thromboembolism: A retrospective-prospective cohort study from 3 Croatian oncology centers Josipa Jovic Zlatovic Received Received
  207-P Correlation between extramural vascular invasion (EMVI) and systemic inflammatory response markers in rectal cancer Cieszymierz Gawi&324;ski Received Received
  208-P Fluoropyrimidinin- and irinotecan-induced toxicity profile associated with mutations in DPYD and UGT1A1 genes Eduardo Terán Brage Received Received
  210-P Germline testing in pancreatic adenocarcinoma Eduardo Terán Brage Received Received
  211-P Claudin-16, its clinical and prognostic value in colorectal cancer Han Gao Received Received
  213-P Is preoperative chemosensitivity associated with improved outcomes in locally advanced gastric cancer? Telma Calea Received Received
  214-P Efficacy and safety of anti-PD-1 agents in patients with dMMR metastatic solid tumours: A retrospective, real-world study Eduardo Terán Brage Received Received
  216-P Serum levels of HMGB1 might have a predictive role for neoadjuvant radiotherapy combined with chemotherapy in rectal cancer patients Temenuzhka Radeva-Petkova Received Received
  217-P Decreased overall survival after resection for colorectal cancer outside working hours Katharina Esswein Received Received
  218-P FOLFIRI as third- or later-line treatment for advanced biliary tract cancer in Northern Thailand Kijjakom Thanasombunsukh Received Received
  219-P Five biomarker mRNAs in combination improve detection of tumor cells and characterize their aggressiveness in lymph nodes from CRC patients Gudrun Lindmark Received Received
  221-P Prognostic value of CD3CD8 T lymphocytes in advanced and metastatic PDAC Skaiste Tulyte Received Received
  222-P GA CPI 613: A single arm, open-label phase I study of CPI-613 in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer Daniel Zaldumbide Received Received
  224-P Toxicity and tolerability of the mFOLFIRINOX regimen in young elderly and older elderly patients with pancreatic carcinoma (PC) Mariam Manukyan Received Received
  226-P Outcomes using induction chemotherapy followed by long-course chemoradiotherapy as total neoadjuvant therapy for locally advanced rectal cancer Mithun Kumaran Received Received
  227-P Overexpression of survivin-1, TAG-72 si HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea Coast geographical area Andra Iulia Suceveanu Received Received
  228-P Gastrointestinal stromal tumours: Real-world data from a Portuguese oncological center Diogo Silva Received Received
  229-P Comparison of clinicopathological and survival features of right and left colon cancers: Experience of the medical oncology department of Fez Soukaina El Anssari Received Received
  230-P The effect of duration of induction therapy on survival in patients receiving maintenance therapy in the first line for metastatic colorectal cancer: A single-center retrospective analysis Nika Librenjak Received Received
  231-P Impact of COVID-19 on colorectal cancer management: Single-center experience Diogo Silva Received Received
  232-P Impact of the IDEA collaboration results on the management of stage II-III colon cancer: 2 years of data from the medical oncology department in Marrakech-Morocco Mohammed El Fadli Received Received
  233-P Real-world outcomes of anal cancer patients treated with radical chemoradiation Ana Barbosa Received Received
  234-P Association between tumor differentiation grade and TNM staging in colorectal cancer Xhensila Pemaj Received Received
  235-P Elevated protein tyrosine phosphatase kappa expression is associated with disease progression and poor prognosis of pancreatic cancer Ziqian Fang Received Received
  237-P Percentage of residual fibrosis versus Rubbia-Brandt classification as predictors of overall survival in metastatic colorectal cancer. Which is better? XAVIER HERNANDEZ-YAGE Received Received
  238-P Pattern of failure after radiotherapy for squamous cell carcinoma of the anus Karen Wind Received Received
  239-P Management of gastric cancer in vulnerable patients: Is there a particularity? Nadin Shawar Al Tamimi Received Received
  240-P Stage II colon cancer: Epidemiological, clinical characteristics, and therapeutic results. Experience of the medical oncology department of Fez Youssef Elhaitmy Received Received
  241-P Risk factors of recurrence rectal cancer after neoadjuvant chemoradiotherapy Mohammed El Fadli Received Received
  242-P Colorectal cancer in young adults: Experience of the medical oncology department of Fez Youssef Elhaitmy Received Received
  243-P Impact of relative dose intensity of bevacizumab in first-line treatment of hepatocellular cancer Suat Ying Lee Received Received
  244-P Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer Samuel Cytryn Received Received
  245-P Value of liquid biopsy in faster medical decisions in colorectal cancer patients: Its clinical application in an Argentinean cancer institution Herman Perroud Received Received
  246-P Real-world outcomes in metastatic colorectal patients receiving regorafenib treatment in China Wang Qu Received Received
  247-P Outcomes of randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma Abdelrahman Yousef Received Received
  250-P A novel small molecule inhibits enzyme associated with colorectal cancer Paramasivam Arumugam Received Received
  251-P Outcomes in patients with locally advanced esophageal cancer after neoadjuvant concurrent chemoradiation: A retrospective study from low- to middle-income countries Shanila Ahmed Received Received
  252-P Real-world data: Different administration strategies of fruquintinib for metastatic colorectal cancer Jianzheng Wang Received Received
  253-P Efficacy and safety of immune checkpoint inhibitors in elderly HCC patients: A real-world study Jiamin Cheng Received Received
  255-P Outcome of local radiation therapy in oligo-recurrent biliary tract cancers Shivakumar Gudi Received Received
  259-P Role of carcinoembryonic antigen as a prognostic marker in colorectal cancer Marsela Sina Received Received
  260-P Differences between right and left colon cancer among Albanian patients Marsela Sina Received Received
  261-P Epidemiological evolution of colorectal cancer over 10 years: Incidence, mortality and survival: Experience of the medical oncology department of Fez Soukaina El Anssari Received Received
  262-P Response to perioperative chemotherapy in locally advanced gastric cancer Denise Magalhães Received Received
  263-P ON203: A new antibody targeting the oxidized form of macrophage migration inhibitory factor demonstrates antitumorigenic activity and TME modulation in patient-derived CRC tumoroids Barbara Maurer Received Received
  264-P The molecular-metabolic interplay in metastatic gastrointestinal stromal tumors (GISTs): The predictive role of body mass index Lorena Incorvaia Received Received
  266-P Expression of HSP60 in colorectal cancer and implication in chemotherapeutic responses Jianyuan Zeng Received Received
  267-P The controversial association of CHEK2 pathogenic variants and colorectal cancer susceptibility Pedro Freitas Received Received
  268-P Molecular signature and MMR status of early- and late-onset colorectal cancer among Arabs Adhari AlZaabi Received Received
  269-P Malignant tumors of the appendix: A retrospective study Fatima Ezzahra Laparde Received Received
  271-P Frequency of RAS variants in Bulgarian patients with metastatic colorectal cancer Maria Radanova Received Received
  272-P Estrogen receptors influence the epithelial-to-mesenchymal transition of pancreatic cancer cell lines Fabrizio Licitra Received Received
  273-P Pancreatic cancer as a systemic disease real-world data from a Portuguese oncological centre Denise Magalhães Received Received
  278-P Impact of surgical resection for gastrointestinal stromal tumors (GISTs) patients with initially diagnosed synchronous hepatic metastases on long-term survival outcomes Jian Wang Received Received
  280-P Neoadjuvant immunotherapy in advanced mismatch repair deficient intestinal cancer Harriet Baker Received Received
  281-P Importance of tumor sampling in transcriptomics-based risk stratification Vlad Popovici Received Received
  282-P Impact of death-associated protein-3 (DAP3) and DAP3 binding cell death enhancer 1 (DELE1) on drug sensitivity in colorectal cancer cells Laijian Sui Received Received
  283-P Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in Stage 1-3 colorectal cancer (CRC) in clinical practice Bradley Somer Received Received
  284-P Genes associated with angiogenesis may be regulated by metabolic radiotherapy on cholangiocarcinoma cells Rafael Ferreira Received Received
  285-P Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study Marc Díez García Received Received
  286-P Prognostic factors for pancreatic adenocarcinoma: Prognostic nutritional index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio Diogo Silva Received Received
  287-P Real-world data of perioperative FLOT in resectable gastric and gastro-esophageal junction junction cancer: The experience of a Portuguese institution M Isabel Vilas-Boas Received Received
  288-P Pancreatic cancer: Epidemiological factors, clinical characteristics, and therapeutic management: Data of an oncology center in southern Morocco Fatima-Zahra Abbassi Received Received
  289-P Study of the hedgehog signaling pathway in colorectal cancer: Association with wild type RAS status Nadia Ben Jemii Received Received
  290-P Real-world evidence of anlotinib in patients with advanced hepatocellular carcinoma and clinical role of a-fetoprotein Bruce Yin Received Received
  291-P PIK3CA mutations in Tunisian patients with metastatic colorectal cancer: A more patients stratification for targeted therapies Amira Jaballah-Gabteni Received Received
  292-P Endoscopic ultrasound guided-fine needle aspiration for the diagnosis of secondary pancreatic lesions. Experience of a reference center POLYXENI KEVREKIDOU Received Received
  293-P Increased expression of dual-specificity phosphatase 7 in gastric cancer is associated with poor prognosis and chemoresistance Yali Xu Received Received
  295-P Prognostic impact of clinico-pathologic parameters in early- and average-onset curatively resected colorectal cancer Ilit Turgeman Received Received
  296-P Neoadjuvant chemotherapy in locally advanced cardia tumor Abdolali shahrasbi Received Received
  297-P Prognostic impact of primary tumor location on synchronous and metachronous colorectal liver metastases: A retrospective monocentric real-life analysis Carlo Signorelli Received Received
  298-P Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress Jong-Mu Sun Received Received
  299-P Real-world assessment of treatment sequencing of patients with advanced pancreatic cancer in a private practice in Rio de Janeiro / Brazil (Americas Oncologia RJ) TUANE BORGES DO L. FREITAS Received Received
  300-P Study of the composition of the inflammatory infiltrate in patients with colorectum cancer Wider Dorra Received Received
  301-P Pre-surgical carcinoembryonic antigen as a recurrence biomarker in stage III colon cancer treated with adjuvant chemotherapy in a Latin American center Eder Christian Veramendi cabana Received Received
  302-P Analysis of risk factors for recurrence of distal bile duct cancer without lymph node metastasis after curative resection: Is adjuvant therapy really required? So Jeong Kim Received Received
  303-P From 2012 to 2018: Seven years analysis of NETs, the experience of the Mohamed VI university hospital center in Marrakech Ephraim Lonté Kintossou Received Received
  305-P Oxidized-LDL promotes colorectal cancer progression and growth of human colonoids Jorge R. Toledo Received Received
  306-P Comprehensive geriatric assessment: Complementary tool in patients with neoplasia of the gastrointestinal tract in a Brazilian university hospital Marcos Santos Received Received
  307-P Modulation of the MYC oncogene using programmable epigenetic mRNA therapeutics as a novel therapy for hepatocellular carcinoma William Senapedis Received Received
  308-P PIK3CA and TP53 gene mutations in patients with metastatic colorectal cancer from Northeast Romania Vlad-Adrian Afrasanie Received Received
  309-P In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in pancreatic ductal adenocarcinoma: An interim analysis Christine Nitschke Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
16:27
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

2022 ESMO World Congress on Gastrointestinal Cancer

 

29 June – 2 July 2022 Barcelona
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 29/06/2022 TO 29/06/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert